Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identify and eradicate leukemia stem cells in T-cell acute lymphoblastic leukemia by PD-1 therapy

ABSTRACT: Identify and eradicate leukemia stem cells in T-cell acute lymphoblastic leukemia by PD-1 therapy

PROVIDER: PRJNA890196 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Identify and eradicate leukemia stem cells in T-cell acute lymphoblastic leukemia by PD-1 therapy

Project description:To investigate the characteristics of PD-1+ LSCs in T-ALL, we purified PD-1+ and PD-1– T-ALL cells from the bone marrow (femur and tibia) of T-ALL mice, Pten null T-ALL mice, or PDX recipients. RNA sequencing was performed to explore the differential gene expression and pathway enrichment of PD-1+ LSCs in T-ALL.

2022-12-13 | GSE215392 | GEO

Proteogenomics of High hyperdiploid childhood acute lymphoblastic leukemia

Project description:Proteogenomic analysis and genomic profiling, RNA-sequencing, and mass spectrometry-based analysis of High hyperdiploid childhood acute lymphoblastic leukemia.

2020-01-29 | MSV000084862 | MassIVE

Proteogenomics of High hyperdiploid childhood acute lymphoblastic leukemia

Project description:Proteogenomic analysis and genomic profiling, RNA-sequencing, and mass spectrometry-based analysis of High hyperdiploid childhood acute lymphoblastic leukemia.

2019-02-25 | PXD010175 | Pride

Persistence of targetable lesions, predicted therapy sensitivity and proteomes through disease evolution in pediatric acute lymphoblastic leukemia

Project description:This data set consists of pediatric acute lymphoblastic leukemia (ALL) primary bone marrow biopsies from the BC Children's Hospital BioBank, pediatric ALL cell lines, non-cancer bone marrow biopsies, and few ALL PDX. All files are DIA and searched by Spectronaut with a spectral library.

2023-01-05 | MSV000091012 | MassIVE

A Pre-clinical model of induction therapy and relapse in pediatric acute lymphoblastic leukemia

Project description:The development of a clinically relevant xenograft model of pediatric acute lymphoblastic leukemia, using a 4-drug treatment regimen designed to mimic pediatric remission induction therapy. Relapse and acquired drug resistance in T-cell acute lymphoblastic leukemia (T-ALL) remains a significant clinical problem. This study was designed to establish a preclinical model of resistance to induction therapy in childhood T-ALL to examine the emergence of drug resistance and identify novel therapies. We performed transcription profiling by array of human CD45-positive human lymphocytes from patients with acute pediatric lymphoblastic leukemia, and from xenografted NOD/SCID mice treated with vincristine, daunorubicin, dexamethasone and L-asparagine. Several different treatment regimes were used in this study (VLXD, VLXDR, VLXD2, VXL and VLXD2-ALL31) and are summarised in the protocols associated with this submission.

2013-11-01 | E-MEXP-3916 | biostudies-arrayexpress

Metabolomics of B-cell Acute Lymphoblastic Leukemia in Response to Adipocyte Conditioned Media

Project description:Adipocyte conditioned media (ACM), stromal cell conditioned media (SCM) and unconditioned media (UCM) were added to B-cell Acute Lymphoblastic Leukemia cells (REH and RCH-AcV) either with or without methotrexate (MTX). The metabolomic profiles of the cells was determined by mass spectrometry.

2022-10-07 | ST002383 | MetabolomicsWorkbench

Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemia

Project description:Dysregulation of kinase signaling pathways via mutations favors tumor cell survival and resistance to therapy and it is common in cancer. Here, we reveal a novel mechanism of post-translational regulation of kinase signaling and nuclear receptor activity via deubiquitination in acute leukemia. We observed that the ubiquitin specific protease 11 (USP11) is highly expressed in lymphoblastic leukemia and associates with poor prognosis in this disease. USP11 ablation inhibits leukemia growth in vitro and in vivo, sparing normal hematopoiesis and thymus development, suggesting that USP11 could be a therapeutic target in leukemia. USP11 forms a complex with USP7 to deubiquitinate the oncogenic lymphocyte cell-specific protein-tyrosine kinase (LCK). Deubiquitination of LCK controls its activity, thereby altering T cell receptor signaling. Impairment of LCK activity leads to increased expression of the glucocorticoid receptor transcript, culminating into transcriptional activation of pro-apoptotic target genes, and sensitizes cells to glucocorticoids in primary T cell leukemia patient samples. The transcriptional activation of pro-apoptotic target genes, such as BCL2L11, is orchestrated by the deubiquitinase activity and mediated via an increase in enhancer-promoter interaction intensity. Pharmacological inhibition of USP7 or genetic knockout of USP7 in combination treatment of glucocorticoid displayed improved anti-T-ALL efficacy in vivo. Our data unveil how dysregulated deubiquitination controls signaling pathways, leading to cancer cell survival and drug non-response, and suggest novel therapeutic combinations towards targeting leukemia.

2022-02-28 | MSV000088930 | MassIVE

MicroRNA-sequencing of Brazilian pediatric acute lymphoblastic leukemia

Project description:MicroRNA-sequencing of the bone marrow samples from Brazilian pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL) and T-cell acute lymphoblastic leukemia (T-ALL).

2022-04-13 | E-MTAB-11621 | biostudies-arrayexpress

Tracking Therapy-Resistant Alterations in Childhood Acute Lymphoblastic Leukemia

Project description:Tracking Therapy-Resistant Alterations in Childhood Acute Lymphoblastic Leukemia

| PRJNA1011437 | ENA

Tracking Therapy-Resistant Alterations in Childhood Acute Lymphoblastic Leukemia

Project description:Tracking Therapy-Resistant Alterations in Childhood Acute Lymphoblastic Leukemia

| PRJNA1011438 | ENA